A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain

Am J Ther. 2011 Sep;18(5):340-2. doi: 10.1097/MJT.0b013e3181e70c38.

Abstract

We compared the effects of ibandronate and pamindronate in patients with bone metastases from breast or lung cancer and we found that ibandronate is superior to pamindronate in alleviating pain, improving mobility and quality of life, and reducing bone resorption indices in patients with bone metastases from breast or lung cancer.

Publication types

  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Bone Resorption / drug therapy
  • Bone Resorption / etiology
  • Breast Neoplasms / complications
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Ibandronic Acid
  • Lung Neoplasms
  • Male
  • Middle Aged
  • Pain / drug therapy
  • Pain / etiology
  • Pamidronate
  • Quality of Life

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Pamidronate
  • Ibandronic Acid